Oaktree Acquisition Corp. III Life Sciences Unit Fundamental Analysis (NASDAQ: OACCU)
Oaktree Acquisition Corp. III Life Sciences Unit Fundamental Analysis (NASDAQ: OACCU)
Oaktree Acquisition Corp. III Life Sciences Unit (NASDAQ: OACCU) shows weak financial fundamentals with a PE ratio of 37.66, profit margin of 0.00%, and ROE of 3.46%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 33.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze OACCU's fundamental strength across five key dimensions:
Efficiency Score
WeakOACCU struggles to generate sufficient returns from assets.
Valuation Score
ModerateOACCU shows balanced valuation metrics.
Growth Score
ModerateOACCU shows steady but slowing expansion.
Financial Health Score
ModerateOACCU shows balanced financial health with some risks.
Profitability Score
WeakOACCU struggles to sustain strong margins.
Key Financial Metrics
Is OACCU Expensive or Cheap?
P/E Ratio
OACCU trades at 37.66 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, OACCU's PEG of 0.94 indicates potential undervaluation.
Price to Book
The market values Oaktree Acquisition Corp. III Life Sciences Unit at 1.03 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -219.22 times EBITDA. This is generally considered low.
How Well Does OACCU Make Money?
Net Profit Margin
For every $100 in sales, Oaktree Acquisition Corp. III Life Sciences Unit keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.46 in profit for every $100 of shareholder equity.
ROA
Oaktree Acquisition Corp. III Life Sciences Unit generates $3.27 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $-0.02 in free cash annually.
FCF Yield
OACCU converts -0.17% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
37.66
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.94
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.03
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.73
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.03
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
-0.01
vs 25 benchmark
How OACCU Stacks Against Its Sector Peers
| Metric | OACCU Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 37.66 | 20.24 | Worse (Expensive) |
| ROE | 3.46% | 635.00% | Weak |
| Net Margin | 0.00% | -596.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.84 | Strong (Low Leverage) |
| Current Ratio | 0.73 | 814.87 | Weak Liquidity |
| ROA | 3.27% | 55.00% | Weak |
OACCU outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Oaktree Acquisition Corp. III Life Sciences Unit's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Value, Dividend, Cyclical
EPS CAGR
N/A
Industry Style: Value, Dividend, Cyclical
FCF CAGR
N/A
Industry Style: Value, Dividend, Cyclical